Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Accumulating evidence suggests that peroxisome proliferator-activated receptor-gamma (PPARgamma)-binding ligands, currently used to treat diabetes, could be used to treat melanoma. Dissociation of their effects on apoptosis from pharmacological activity (i.e., PPARgamma activation) provides a molecular basis for exploiting these compounds to develop molecularly targeted anticancer agents. In this issue, Botton and co-workers demonstrate in vitro and in vivo antimelanoma effects of ciglitazone, a synthetic ligand-activating PPARgamma.
Schadendorf
Dirk
D
Department of Dermatology, Venerology, and Allergology, University Hospital Essen, Essen, Germany. dirk.schadendorf@uk-essen.de
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists* / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; C039671:ciglitazone